{"doi":"10.1007/s00125-016-4150-x","title":"Peptide serum markers in islet autoantibody-positive children","abstract":"<h4>Aims/hypothesis</h4>We sought to identify minimal sets of serum peptide signatures as markers for islet autoimmunity and predictors of progression rates to clinical type 1 diabetes in a case-control study.<h4>Methods</h4>A double cross-validation approach was applied to first prioritise peptides from a shotgun proteomic approach in 45 islet autoantibody-positive and -negative children from the BABYDIAB/BABYDIET birth cohorts. Targeted proteomics for 82 discriminating peptides were then applied to samples from another 140 children from these cohorts.<h4>Results</h4>A total of 41 peptides (26 proteins) enriched for the functional category lipid metabolism were significantly different between islet autoantibody-positive and autoantibody-negative children. Two peptides (from apolipoprotein M and apolipoprotein C-IV) were sufficient to discriminate autoantibody-positive from autoantibody-negative children. Hepatocyte growth factor activator, complement factor H, ceruloplasmin and age predicted progression time to type 1 diabetes with a significant improvement compared with age alone.<h4>Conclusion/interpretation</h4>Distinct peptide signatures indicate islet autoimmunity prior to the clinical manifestation of type 1 diabetes and enable refined staging of the presymptomatic disease period.","journal":"Diabetologia","year":2016,"id":12271,"datarank":1.5062692592780977,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":0.9606313353191397,"self_endowment_contribution":0.5456379239589579,"citer_contribution":0.9606313353191397,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":33,"citers_with_citation_signal":31,"citers_with_endowment":31,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.0491,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2016-11-04","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":57501,"name":"Michael Laimighofer","orcid":"0000-0003-1708-0302","position":1,"is_corresponding":false},{"id":96909,"name":"Peter Achenbach","orcid":"0000-0001-6720-2684","position":2,"is_corresponding":false},{"id":55954,"name":"Andreas Beyerlein","orcid":"0000-0001-6603-5036","position":3,"is_corresponding":false},{"id":96910,"name":"Tonia de las Heras Gala","orcid":null,"position":4,"is_corresponding":false},{"id":2337,"name":"Jan Krumsiek","orcid":"0000-0003-4734-3791","position":5,"is_corresponding":false},{"id":42,"name":"Fabian Joachim Theis","orcid":"0000-0002-2419-1943","position":6,"is_corresponding":false},{"id":96911,"name":"Anette G. Ziegler","orcid":null,"position":7,"is_corresponding":false},{"id":25246,"name":"Stefanie M. Hauck","orcid":"0000-0002-1630-6827","position":8,"is_corresponding":false},{"id":96908,"name":"Christine von Toerne","orcid":"0000-0002-4132-4322","position":0,"is_corresponding":true}],"reference_count":43,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-03-01T18:20:47.508186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}